A natural extract shows promising results in a published clinical study. The marketing team builds a launch around the finding. The regulatory team asks two questions: can you defend the dose in the product? Can you defend the claim on the label? Both answers, six months later, turn out to be "no."
The functional food and beverage category lives on a tension between science and storytelling. On one side, a growing body of clinical research on bioactive compounds — polyphenols, prebiotics, peptides, plant extracts, postbiotics. On the other, a regulatory framework that requires careful translation between "showed a benefit in a study" and "you can say this on a package." The brands that grow durably in this category understand that gap and design products to close it.
For a manufacturer, the cost of getting this wrong is not theoretical. It includes withdrawn claims, regulatory action, retailer delistings, and erosion of consumer trust — not necessarily because the ingredient was wrong, but because the system around it was insufficient.
What "clinical evidence" actually requires to support a label claim
A published study showing a benefit is the starting point, not the endpoint. To translate that evidence into a defensible label claim, four conditions typically need to be met:
- Dose alignment — the amount of bioactive in the product, per serving, needs to match (or exceed, depending on jurisdiction) the dose that produced the effect in the study.
- Form equivalence — the form of the bioactive (extract, standardized, isolated compound) needs to be reasonably comparable to what was studied. A study on a specific standardized extract does not automatically support claims for a different extract of the same plant.
- Population relevance — the study population needs to be reasonably representative of the consumer the product is targeting.
- Regulatory acceptance — the claim wording needs to fit within the categories permitted by the relevant authority (general function, reduction of disease risk, structure-function, etc.).
Each jurisdiction handles these conditions differently. A claim acceptable in one market may be restricted in another; a study sufficient for one regulator may not be sufficient for the next.
The four types of bioactives and what each requires
Standardized plant extracts
Examples: green tea catechins, grape seed proanthocyanidins, curcumin extracts, ashwagandha extracts. The key question is standardization: which compound is the active, at what concentration, and how is it verified batch to batch? Two extracts of the same plant can differ by 10× in active content. A label claim that worked with one extract may not be defensible with another.
Isolated or synthetic actives
Examples: vitamins, minerals, amino acids, isolated peptides, specific carotenoids. Easier to dose precisely and verify analytically. Regulatory pathway often clearer, though specific markets vary on permitted levels and claims.
Probiotics, prebiotics, postbiotics
Examples: specific bacterial strains, inulin, fructooligosaccharides, fermentation metabolites. Claims usually require strain-specific or substance-specific evidence — "probiotics help digestion" is not the same regulatory category as "this specific strain at this dose has been shown to support gut comfort." Strain identity, viable cell count through shelf life, and clinical evidence on that specific strain are all required.
Functional macronutrients
Examples: fiber, omega-3 (EPA/DHA), protein, plant sterols. Generally well-characterized with established claim categories in most markets, though dose thresholds and exact wording vary by jurisdiction.
Red flags when evaluating a new bioactive ingredient
If a proposed functional ingredient shows any of the following, careful additional validation is warranted before committing to a product launch:
- Clinical claims based on a single small study, or studies in populations or doses very different from the target product.
- Supplier marketing language that paraphrases study findings as broader claims than the studies actually support.
- Lack of standardization or batch-to-batch variability in active content.
- Stability of the active in the product matrix not validated under real distribution conditions.
- Regulatory status not confirmed in the specific target markets — including allowed claim wording, dose thresholds, and labeling requirements.
Where a sourcing partner adds value
The bioactive ingredient market is one of the most heterogeneous categories in food and beverage. Suppliers vary widely in scientific rigor, regulatory expertise, and willingness to support claims with technical dossiers. A sourcing partner with category knowledge can help evaluate the strength of clinical evidence behind a proposed ingredient, distinguish between standardized and unstandardized forms, assemble the regulatory documentation needed to defend claims in target markets, and propose alternative ingredients or claim categories that may be more defensible for a given product positioning.
This is one of the few categories where the cost of the ingredient is rarely the limiting factor. The limiting factor is the strength of the case behind it.
The takeaway
A bioactive ingredient supports a product claim only when dose, form, population evidence, and regulatory wording align across the entire chain — supplier, formulation, label, and target market. The brands building durable functional portfolios validate each of these four conditions before launch, not after. Ingredient selection is one variable among many — but a partner who can support the case in front of regulators and retailers is what turns a hopeful claim into a defensible one.
This article is provided for general informational purposes only and does not constitute regulatory, scientific, or commercial advice. Specific claim requirements vary substantially by jurisdiction and product category, and any health-related claim must be validated against the applicable regulatory framework with appropriate expert support.
